Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia

KAMIL WDOWIĄK1, ENRIQUE GALLEGÓ-COLON2, TOMASZ FRANCUZ1,2, PAULINA CZAJKA-FRANCUZ1, NATALIA RUIZ-AGAMEZ2, MARCIN KUBECZKO3, IGA GROCHOLA1, MACIEJ T. WYBRANIEC4, JERZY CHUDEK1 and JERZY WOJNAR4

1Department of Internal Medicine and Oncological Chemotherapy, Silesian Medical University, Katowice 40-027; 2Department of Biochemistry, Silesian Medical University, Katowice 40-752; 3Clinical and Experimental Oncology Department, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice 44-101; 4First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice 40-635, Poland

Received March 13, 2018; Accepted September 11, 2018

DOI: 10.3892/ol.2018.9656

Abstract. Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. Despite improvements in treatment, CLL is still considered an incurable disease. The aim of the present study was to evaluate galectin-1, -3 and -9 (Galectin-1, -3 and -9) and Gal-3 binding protein (Gal-3BP) as prognostic and predictive factors in patients with CLL. Serum concentrations of Galectin-1, -3 and -9 and Gal-3BP were measured in 48 patients with CLL and 30 control patients, using multiplex bead arrays. In patients with CLL, galectin concentrations were assessed prior to, during and following treatment. In patients with CLL who were untreated, galectin concentrations were measured twice with a 6-month interval. The serum level of Gal-9 was significantly increased (P<0.0001) in patients with CLL compared with the control group, and was associated with the clinical stage according to Binet classification, as well as poor cytogenetic and serum CLL prognostic factors. In addition, patients with CLL, who exhibited treatment failure, exhibited higher concentrations of Gal-9 (P=0.06) and Gal-3BP (P=0.009) at the end of the treatment when compared with patients under complete remission or stabilization of the disease. The serum level of Gal-3 was significantly decreased (P=0.012) in patients with CLL compared with the control group. These results suggest that Gal-9 is a potential prognostic factor in patients with CLL. The predictive value of Gal-9 requires further study in larger cohorts of patients.

Introduction

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries with a large percentage of asymptomatic patients, and may be detected only incidentally during routine examinations (1,2). CLL is a disease that exhibits a gradual onset, and is characterized by the accumulation of small defective CD5+ B lymphocytes in the blood, bone marrow and lymphoid organs (3). The disease presents with subtle and heterogeneous symptoms, including fever, night sweats, weight loss, lymphadenopathy, anemia, and thrombocytopenia that are often missed at early stages (1). Even following diagnosis, due to the slow progression of CLL, patients may not require chemotherapeutic treatment (2,3).

The heterogeneous presentation and clinical course of CLL makes stratification of patients into appropriate risk and treatment groups of great importance. CLL has been associated with chromosomal abnormalities, including trisomy 12q (16%), deletion of 11q (18%) and deletion of 17p [7%, containing tumor protein p53 (TP53)], which is associated with a shorter survival time, aggressiveness of disease and extensive lymph node involvement (4,5). Notably, the most common chromosomal aberration, deletion of 13q (55%), correlates with good prognosis in 55% of patients with CLL (4,5). CLL heterogeneity is partially caused by microRNA (6,7), epigenetic (8) and microenvironment alterations (3). At present, the strongest prognostic indicator in CLL is the mutational status of the immunoglobulin heavy-chain variable region (IGHV), which predicts clinical prognosis at diagnosis (9,10). Mutation of IGHV is correlated with slower disease progression and an increased survival time, in addition to the less advanced Binet stage A disease (11). However, routine determination of this biomarker is not a cost-effective measure, and thus not widely used. Other markers, including CD38 and ZAP70, have also been investigated as surrogates for IGHV status (12,13); however, a reliable marker has yet to be identified. CD38 expression correlates with non-mutated IGHV, adverse disease course and severity, whereas ZAP70 expression is associated with mutated IGHV.
and an improved disease outcome (12-18). For >40 years, Rai and Binet staging systems have served as standardized systems to categorize patients, provide patient care and administer adequate cancer therapy (19,20). However, in order to continue to improve patient outcomes, more accurate prognostic markers are required. Additionally, important factors, such as lactate dehydrogenase (LDH) and β2 microglobulin (B2M) indicate the proliferation and activity of the disease (21). Lower B2M serum concentrations have been identified as beneficial prognostic factors associated with a higher response rate, longer disease-free time and overall survival (OS) times (21). However, in clinical practice, the prognostic and predictive value of B2M and LDH remains insufficient. Therefore, it is imperative to identify novel indicators that may aid clinicians in making an informed decision regarding when to begin treatment.

The 'sugar code', or protein glycosylation pattern, serves a role in intra- and intercellular communication, and exhibits functions in regulatory processes, including those dysregulated in cancer and metastasis (22-24). Galectins are glycans-binding proteins of the lectin family, and are central effectors of this form of communication, and their role has previously been implicated in the development of cancer (25). All 15 of the galectins identified in humans share a highly conserved carbohydrate recognition domain (CRD) that recognizes and binds β-galactosides (26). This CRD-mediated pattern recognition mechanism promotes galectin binding to specific cell surface receptors, activating intracellular signaling pathways involved in immune response, cell adhesion, communication, proliferation, differentiation and migration (27,28). The role of galectins in cancer progression is an area of interest in current research. Different galectins are associated with tumor progression and suppressive mechanisms that are specific to the type of tumor (29). High plasma levels of galectins -2, -4, -8 and -10 (Gal-2, -4, -8 and -10) have been observed in patients with various types of malignancy, including ovarian carcinoma, prostate cancer and metastatic diseases (30,31). Galectins induce the secretion of cytokines and chemokines, including granulocyte colony-stimulating factor, interleukin-6 and chemokine (C-X-C) motif ligand 1, thereby promoting cancer-endothelial cell adhesion and promoting metastasis (30,32). Gal-9 also serves a central role in tumor cell-induced T-cell exhaustion in CLL (32). Taglihoo et al (32) identified that Gal-9 levels were increased 30-fold in the malignant cells of patients with CLL. Levels of PL-1, a known effector of apoptosis in T cells, were also increased. Additionally, extracellular Gal-3 has been demonstrated to induce T-cell apoptosis in melanoma, and its suppression leads to enhanced migration and invasion of cholangiocarcinoma cells (33). Reduced levels of Gal-3 enhance the activation of apoptosis via cell-to-cell contact (33). Notably, low Gal-3 levels are associated with a progressive form of cervical neoplasia (34). In addition, intracellular Gal-3 may be involved in mRNA splicing and correlates with poor prognosis (35-37). Gal-9 is able to bind Tim-3, preventing T-cell activation and triggering cell death in Tim-3+ T cells (38-40). This dampening of the T-cell mediated immune response is also supported by Gal-1 expression, which induces anti-inflammatory macrophage activation and expansion of the regulatory T-cell compartment (26,41,42). Due to the role of galectins in cancer progression, the aim of the current study was to evaluate serum levels of galectins as potential prognostic factors in patients with CLL.

Materials and methods

Patients. This prospective study included 52 patients (Tables I and II) with CLL admitted to the Department of Internal Diseases and Oncological Chemotherapy (Mielęcki's Independent Public Clinical Hospital of the Silesian Medical University in Katowice) for immunochemotherapy or chemotherapy between March 2013 and September 2017, and 30 non-CLL patients as control subjects. Control patients were admitted to the Department of Endocrinology (Mielęcki's Independent Public Clinical Hospital of the Silesian Medical University in Katowice) for routine MRI imaging of adrenal gland incidentaloma. None of the control patients had a hormonally active tumor or CLL. Patients with CLL were classified according to the Binet staging system (19,20).

The exclusion criteria were as follows: Other malignancies, acute inflammatory diseases or a history of renal or liver disease or heart failure (>New York Heart Association Functional Classification III/IV). Based on the exclusion criteria, 4 patients with CLL were disqualified from the study. Therefore, a total of 48 patients, 23 male and 25 female patients, with an average of 64 years of age, with CLL were included. Additionally, all patients in the control group met the exclusion criteria. Study subjects underwent assessment of total blood count, serum activity of LDH, and levels of B2M, creatinine, glucose and immunoglobulins IgG, IgA and IgM. A bone marrow biopsy was performed in each patient. Additionally, fluorescent in situ hybridization was performed to assess chromosomal abnormalities, including del11q, del17p and del13q, as well as trisomy of chromosome 12. The decision between initiation of chemotherapy or a ‘watchful waiting’ strategy was made according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines (43-45). Patients with CLL who required systemic treatment received chemotherapy comprising rituximab, fludarabine, cyclophosphamide, vincristine, prednisone and bendamustine (R-FC, R-COP or R-B schemes) according to schedules based on the patient's clinical condition. The present study was performed in adherence with the Declaration of Helsinki Guidelines and was approved by the Bioethics Committee of Silesian Medical University in Katowice (approval no. KNW/0022/KBI/102/13). Upon admission, all patients provided written informed consent for their participation in this project.

Blood samples. Blood (10 ml) was collected from each subject prior to chemotherapy. Whole blood samples were stored in Vacutainer tubes containing a coagulation activator, and were left to clot. Following 20 min of incubation at room temperature, the samples were centrifuged for 10 min at 1,000 x g at room temperature. Serum aliquots were frozen and stored at -176°C in liquid nitrogen until subsequent analysis. In addition, patients with CLL who underwent treatment were re-evaluated during chemotherapy (3 months) and following chemotherapy (6 months). Untreated patients with CLL (with stable disease, SD) were re-evaluated for the second measurement at 6 months. Control patients were assessed during the same period.

Fluorescent bead-based Luminex cytokine assay. Analysis of galectin protein concentrations was performed in patient sera using multiplex, bead-based assays customized for
the selected galectins (cat. no., LXSAHM; R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer's protocol. Galectin protein levels were analyzed prior to chemotherapy, during chemotherapy (3 months) and following chemotherapy (6 months). All the detection antibodies used produced a single band in the western blot analysis, with a molecular mass corresponding to the detected galectin (data not shown). Where available, except standards (recombinant human galectins), external galectin standards were used to assess potential cross-reaction. No significant cross-reactivity or sensitivity issues were identified among the assayed galectins (data not shown). According to the multiple bead-based assay manufacturer’s protocol, biotinylated anti-Gal-9 antibody has <2% cross-reactivity with rhGalectin-1, rhGalectin-2, rhGalectin-7 and rhGalectin-8. Due to the different dilutions required for the assay, separate assays were performed for Gal-1 and Gal-9, and Gal-3 and Gal-3BP. Data were acquired on a validated and calibrated Bio-Plex 200 system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and analyzed with Bio-Plex Manager 6.0 software (Bio-Rad Laboratories, Inc.) with a detection target of 50 beads/region, low RP1 target for CAL2 calibration, and recommended doublet discriminator gates of 8,000-16,500 for Bio-Plex. The median fluorescence intensity was measured.

Statistical analysis. Statistical analysis was performed using Statistica (version 10; StatSoft, Inc., Tulsa, OK, USA) and MedCalc v.14.8.1 (MedCalc Software bvba, Ostend, Belgium) software packages. Continuous variables are expressed as the mean ± standard error of the mean (normally distributed) or as the median and interquartile range (non-normally distributed). The type of distribution was established based on the Shapiro-Wilk test. Qualitative variables were expressed as crude values and percentages. Intergroup differences for normally distributed quantitative variables were assessed using the paired student’s t-test or one-way analysis of variance followed by Dunnett's multiple comparison post hoc test. The Kruskal-Wallis test was applied for parameters with a skewed distribution. Temporal variations of different variables were evaluated using the paired student's t-test for dependent samples or Wilcoxon matched pairs test. Mortality or disease progression were defined as dependent variables for the purpose of the univariate and multivariate Cox proportional hazards model, whereas independent variables were designated from among baseline and laboratory parameters, including plasma galectin concentration. Hazard ratios with 95% confidence intervals were calculated. Kaplan-Meier estimator curves were established and compared using the log-rank test in order to compare survival between qualitative

| Variable                | Control | Upper-lower quartile | CLL patients | Upper-lower quartile | P-value |
|-------------------------|---------|----------------------|--------------|----------------------|---------|
| Age                     | 64      | 72-55                | 70.5         | 76-65                | 0.027   |
| Platelet (10^9/l)       | 238.6   | 270-205              | 160.81       | 203-111              | <0.001  |
| Haemoglobin (g/l)       | 13.93   | 15.3-12.7            | 12.23        | 14.1-10.9            | 0.001   |
| Leukocytes (10^9/l)     | 7.61    | 8.86-5.87            | 68.59        | 89.62-24.44          | <0.001  |
| BMI                     | 27.52   | 29.72-25.56          | 27.32        | 29.75-24.35          | 0.430   |

Data are presented as median (interquartile range) or mean ± standard deviation (SD). Paired t-test Fisher. DM, Diabetes mellitus; CHD, chronic heart disease; CLL, chronic lymphocytic leukemia. One-way analysis of variance with Bonferroni post-hoc test.

| CLL staging   | Control | CLL patients | LN involvement | Spleen involvement | LDH (SD) | B2M (SD) |
|---------------|---------|--------------|----------------|--------------------|----------|----------|
| Binet A       | n/a     | 14           | 10             | 1                  | 157.8±23.99 | 3,444±1546 |
| Binet B       | n/a     | 15           | 14             | 8                  | 199.9±51.53 | 4,671±2187 |
| Binet C       | n/a     | 19           | 20             | 15                 | 231.4±99.64^a | 5,169±2915 |

**Table I. Clinical and laboratory patient information in control and patients with chronic lymphocytic leukaemia.**

| Variable       | Control | CLL patients | Upper-lower quartile |
|----------------|---------|--------------|----------------------|
| Age            | 64      | 72-55        | 70.5                 |
| Platelet (10^9/l) | 238.6   | 270-205      | 160.81               |
| Haemoglobin (g/l) | 13.93   | 15.3-12.7    | 12.23                |
| Leukocytes (10^9/l) | 7.61    | 8.86-5.87    | 68.59                |
| BMI            | 27.52   | 29.72-25.56  | 27.32                |

Data are presented as median (interquartile range) or mean ± standard deviation (SD). Paired t-test Fisher. DM, Diabetes mellitus; CHD, chronic heart disease; CLL, chronic lymphocytic leukemia. One-way analysis of variance with Bonferroni post-hoc test.

| CLL staging | Control | CLL patients | LN involvement | Spleen involvement | LDH (SD) | B2M (SD) |
|-------------|---------|--------------|----------------|--------------------|----------|----------|
| Binet A     | n/a     | 14           | 10             | 1                  | 157.8±23.99 | 3,444±1546 |
| Binet B     | n/a     | 15           | 14             | 8                  | 199.9±51.53 | 4,671±2187 |
| Binet C     | n/a     | 19           | 20             | 15                 | 231.4±99.64^a | 5,169±2915 |

**Table II. Clinical patient information in control and patients with chronic lymphocytic leukaemia.**

Data are presented as median (interquartile range) or mean ± standard deviation (SD). CLL, chronic lymphocytic leukemia; LDH, lactate dehydrogenase; B2M, β2 microglobulin; LN, lymph node. ^a p<0.05.
parameters. P<0.05 was considered to indicate a statistically significant difference. Spearman’s Rank-Order correlation was used to perform correlation analysis between GAL-9 and LDH and GAL-9 and B2M.

Results

Patient characteristics. Patients were stratified according to Binet staging (Tables I and II) and subdivided according to disease progression. Significant differences in age, platelets, hemoglobin and leukocytes were observed between patients with CLL and the control group (Tables I and II). No significant increases in comorbidities were observed in the CLL group when compared with the control group.

Serum concentrations of Gal-1, -3, -9 and Gal-3BP in patients with CLL. Gal-1, -3, -9 and Gal-3BP levels in the sera from 48 patients with CLL and 30 control subjects are presented in Fig. 1. Gal-9 levels were significantly elevated in patients with CLL compared with the control group (14 vs. 8 ng/ml; P<0.0001; Fig. 1B), whereas Gal-3 levels were significantly reduced (7 vs. 8 ng/ml; P<0.05; Fig. 1C). No statistically significant differences in Gal-1 and Gal-3BP protein were observed between patients with CLL and the control group (Fig. 1A and D).

Association between galectin levels and CLL prognostic factors. Association analysis between negative cytogenetic factors, including deletions of 11q (del11q), 17p (del17p) and 13q (del13q), were analyzed (Fig. 2). Patients with del11q and del17p presented with higher levels of Gal-9 when compared with patients with CLL and no chromosomal abnormalities (17 vs. 12 ng/ml; P<0.05; Fig. 2A). When analyzed individually, patients with del11q exhibited a statistically significant increase in levels of Gal-1 (39 vs. 10 ng/ml; P<0.001) and Gal-9 (13 vs. 9 ng/ml; P<0.05) compared with patients with CLL and no chromosomal abnormalities (Fig. 2B and C). Conversely, patients with deletions in del13q presented a significant decrease in Gal-9 levels (13 vs. 18 ng/ml; P<0.05) when compared with the CLL group with no chromosomal abnormalities (Fig. 2D). No significant differences were observed in galectin levels when patients presented with del17p (data not shown). Furthermore, a significant correlation was observed between Gal-9 serum concentration and CLL prognostic factors, including LDH activity (P<0.0001) and B2M level (P<0.0001; Fig. 3).

Serum concentration of Gal-9 correlates with clinical stage of CLL. Serum concentrations of Gal-1, -9 and -3 and Gal-3BP stratified according to patient stage are presented in Figs. 4 and 5 and Tables I and II. Prior to chemotherapy, patients with CLL at Binet stages B and C exhibited increased levels of Gal-9 (17 and 15 ng/ml; P<0.001 and P<0.05, respectively), when compared with patients with CLL at Binet stage A (10 ng/ml; Fig. 4). Following chemotherapy, Gal-9 levels remained elevated in patients with Binet C CLL when compared with patients with Binet A CLL (Fig. 4B). Gal-1, Gal-3 and Gal-3BP levels remained unchanged (Fig. 4A, C and D). Patients in Binet A stage exhibited a significant reduction in Gal-9 protein concentration compared with
patients in Binet C stage at 6 months following chemotherapy (9 vs. 15 ng/ml; P<0.05; Fig. 4B).

Furthermore, galectin protein levels were analyzed prior to chemotherapy, during chemotherapy (3 months) and following chemotherapy (6 months; Fig. 5). The follow-up Gal-1 and Gal-3 levels remained unchanged (Fig. 5A and C). Notably, patients in Binet B stage exhibited a progressive reduction in Gal-9 levels during the follow-up time (17, 14 and 12 ng/ml, respectively; P<0.05; Fig. 5B). Additionally, Gal-3BP levels increased in patients in Binet C stage compared with patients in Binet A stage, following chemotherapy (23 vs. 17 ng/ml; P<0.05; Fig. 5D).

Galectins as prognostic markers for response to treatment and survival. Galectin levels in patients with CLL were evaluated according to the type of response to chemotherapy (Fig. 6). The response to chemotherapy was evaluated according to IWCLL criteria (43-45). Patients with SD exhibited a significant reduction in Gal-9 concentration compared with patients who achieved partial response (PR; 9 vs. 18 ng/ml; P<0.05). No significant associations between Gal-1 or Gal-3BP (Fig. 6A and D) and response to treatment were identified. Notably, untreated patients with SD exhibited lower Gal-9 levels compared with patients who achieved complete remission (CR) following chemotherapy, as well as with patients who exhibited disease progression (PD) and patients who succumbed to the disease during the treatment (Fig. 6B). Notably, Gal-3 levels were significantly elevated in patients who succumbed to the disease compared with patients with CR, PR, SD and PD, with the PD group exhibiting the lowest Gal-3 concentration (Fig. 6C). The established negative prognostic factor for CLL, LDH, did not exhibit a statistically significant difference.

To evaluate the prognostic value of galectin levels in CLL patient sera, Kaplan-Meier survival curves were plotted for Gal-1, Gal-3, Gal-9 and Gal-3BP according to galectin concentration >75th percentile (Fig. 7). During follow-up, 9 patients succumbed and 10 exhibited PD. The median time of progression free survival (PFS) for the CLL group was 19.5 months and an elevated risk of mortality was observed when Gal-9 levels were elevated; however, this was not statistically significant (P=0.19; Fig. 7B). No significant results were observed for elevated Gal-1, Gal-3 and Gal-3BP in the prediction of shorter OS or PFS times (Fig. 7A, C and D). COX analysis indicated no significant results for galectins in the prediction of mortality or progression. A trend was observed in Gal-3 concentration measured prior to treatment (P=0.056; Fig. 7C).

Discussion

Galectins are members of the lectin family, which exhibit a high affinity for β-galactosides. The galectin-glycan conjugate serves a fundamental role in metastasis, angiogenesis, tumor immunity, proliferation and apoptosis (25,26). Unfortunately, the mechanism of action and potential therapeutic implications of galectins in cancer are not yet fully understood (29,32,46).

In a study by Asgarian-Omran et al (29), low mRNA expression of the Gal-3 gene was observed in the leukemic cells of patients with CLL, and no significant difference was observed in Gal-1 mRNA between CLL patients and control subjects. In addition, expression of Gal-3 mRNA was lower in patients with.
progressive disease. In the current study, a reduction in Gal-3 plasma levels was observed in patients with CLL compared with controls. In a study by Taghiloo et al (32), galectin levels were compared in 25 patients with CLL and 15 healthy subjects, and high mRNA expression levels of Gal-9 were observed in mononuclear cells of patients with CLL. In a previous study, plasma levels of Gal-1 were measured in 49 patients with CLL and 40 healthy subjects, the study revealed an increase in Gal-1 in patients with CLL compared with healthy subjects (32). In patients at Binet C stage, plasma Gal-1 levels were identified to be increased >2-fold when compared with patients at stage Binet A (517 vs. 208 ng/ml) (46). However, in the current study, Gal-1 levels were similar between CLL and controls. There are limitations to the present study, for example, at the design stage, the association between IGHV, and Gal-1 and Gal-3 levels were not investigated as according to the literature, the mutational status of the IGHV has no effect on the expression of Gal-1 and Gal-3 (29). Additionally, due to the limited number of patients enrolled in the present study, statistical analyses to assess the association between galectin level and mutational status of IGHV were not performed. The beta value of statistical analysis would not be strong enough to support a possible negative result indicating that there is no correlation between galectin levels and mutational status.

To the best of our knowledge, the current study is the first to describe that patients with CLL exhibit higher serum concentrations of Gal-9, which is associated with the stage of disease. Consistent with these results, Kikushige et al (47) observed higher concentrations of Gal-9 in sera of patients and mice with acute myeloid leukemia (AML) compared with healthy subjects. AML cells secrete Gal-9 via an autocrine loop, which leads to activation of T-cell immunoglobulin and mucin domain-containing protein 3 receptor (Tim-3). Gal-9-dependent T-cell activation promotes leukemic stem cell self-renewal (47).
Figure 4. Galectin serum levels and clinical status in patients with CLL prior to and following chemotherapeutic treatment. Concentration of (A) galectin-1, (B) galectin-9, (C) galectin-3 and (D) galectin-3-binding protein in patients with CLL at Binet stage A, B or C. Data are presented as the mean ± standard error of the mean. Binet A (n=14), Binet B (n=15) and Binet C (n=19). Data were analyzed using one-way analysis of variance followed by Dunnett’s multiple comparison post-hoc test. *P<0.05 for Binet C or **P<0.001 for Binet B when compared with Binet A, respectively, prior to CTH. *P<0.05 for Binet B when compared with Binet A, following 6 months. CLL, chronic lymphocytic leukemia.

Figure 5. Galectin protein levels in patients with CLL stratified by Binet stage. Concentration of (A) galectin-1, (B) galectin-9, (C) galectin-3 and (D) galectin-3-binding protein in patients with CLL at Binet stage A, B or C and prior to chemotherapy (Prior CT), during chemotherapy (3 months) or following chemotherapy (6 months). Binet A (n=14), Binet B (n=15) and Binet C (n=19). Data are presented as the mean ± standard error of the mean. Data were analyzed using one-way analysis of variance followed by Dunnett’s multiple comparison post-hoc test. *P<0.05. CLL, chronic lymphocytic leukemia.
Furthermore, Gal-9 and Tim-3 proteins inhibit the activation of natural killer (NK) cells, blocking the action of NKs on AML cells (48). Subsequently, the Gal-9/Tim-3 signaling pathway is associated with inhibition of the response from Th1 cells in patients with osteosarcoma (49). The Tim-3 receptor, as well as receptors including cytotoxic T-lymphocyte antigen-4
galectin inhibitors, including competitive carbohydrates, small strategies for the treatment of CLL may involve the use of groups of patients should be performed. Future therapeutic findings are limited by the number of patients investigated and progression of CLL or patient mortality. However, these treatment. An association was observed between Gal-9 levels and negative prognostic factors, including del11q, del17p, LDH, B2M and response to treatment. An association was observed between Gal-9 levels and progression of CLL or patient mortality. However, these findings are limited by the number of patients investigated in the present study. Therefore, further studies with larger groups of patients should be performed. Future therapeutic strategies for the treatment of CLL may involve the use of galectin inhibitors, including competitive carbohydrates, small non-carbohydrate binding molecules and antibodies.

Acknowledgements
Not applicable.

Funding
The present study was supported by internal grant from the Medical University of Silesia (grant no. KNW-1-025/K/7/K).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
TF, PF and KW made substantial contributions to the conception and the design of the present study and were involved in the acquisition analysis and interpretation of data. EC was involved in analysis and interpretation of data, and drafting the manuscript. NA, MW, MK and IG performed the statistical analyses and were involved in data management and critical appraise of the manuscript. TF, JC and JW contributed to the study design and the critical revision and final approval of the present manuscript. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate
The study was conducted in adherence with the Declaration of Helsinki Guidelines and was approved by the Bioethics Committee of Silesian Medical University in Katowice (approval no. KNW/0022/KBi1/102/13). Upon admission, all patients provided written informed consent for their participation in this project.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Shanafelt TD, Byrd JC, Call TG, Zent CS and Kay NE: Narrative review: Initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med 145: 435-447, 2006.
2. Zenz T, Mertens D, Kiipper R, Döhner H and Stilgenbauer S: From pathogenesis to treatment of chronic lymphocytic leukemia. Nat Rev Cancer 10: 37-50, 2010.
3. Zhang S and Kipps T: The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol 9: 103-118, 2014.
4. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M and Lichter P: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910-1916, 2000.
5. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J and Rai K: Chronic lymphocytic leukemia. Nat Rev Dis Primers 3, 16096, 2017.
6. Balatti V, Pekarky Y and Croce CM: Role of microRNA in chronic lymphocytic leukemia onset and progression. J Hematol Oncol 8: 12, 2015.
7. Fabbri M, Bottino A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, et al: Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 305: 59-67, 2011.
8. Martin-Subero JI, López-Otín C and Campo E: Genetic and epigenetic basis of chronic lymphocytic leukemia. Curr Opin Hematol 20: 362-368, 2013.
9. Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H and Stilgenbauer S: V(HE) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100: 1410-1416, 2002.
Chen C, Duckworth CA, Zhao Q, Pritchard DM, Rhodes JM and Yu LG: Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res 17: 1693-1704, 2013.

Colomb F, Wang W, Simpson D, Zafar M, Beynon R, Rhodes JM and Yu LG: Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells. J Biol Chem 292: 8381-8389, 2017.

Taghioo A, Allabandeh H, Elahi R, Tehrani M, Hosseini-Kazh, Janbabaei G, Shekarzirz and Asgarian-Omran H: Upregulation of Galectin-9 and PD-L1 immune checkpoints molecules in patients with chronic lymphocytic leukemia. Asian Pac J Cancer Prev 18: 2269-2274, 2017.

Jung M and Wongham C: Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinoma. Eur J Cancer, 44: 619, 2008-626.

Lee JW, Song SY, Choi JJ, Choi CH, Kim TJ, Kim J, Lee JH, Kim BG and Bae DS: Decreased galectin-3 expression during the progression of cervical neoplasia. J Cancer Res Clin Oncol 132: 241-247, 2006.

Matsuda S, Yamagishi Y, Fukushima K, Ueno Y and Shimosegawa T: Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 38: 1110-1111, 2008.

Pietro VG, Mourad-Zeidan AA, Melnikova Y, Johnson MM, Lopez A, Diwan AH, Lazor AJ, Shen SS, Zhang PS, Reed JA, et al: Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 12: 6707-6715, 2006.

Nakahara S, Oh W, McClure H, et al: On the role of galectin-3 in cancer apoptosis. Apoptosis 10: 267-275, 2005.

Koyama S, Abkay E, Li YY, Herter-Sprie GS, Buczkwoski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al: Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7: 10501, 2016.

Sakushi K, Apebort L, Sullivan JM, Blazar BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207: 2187-2194, 2010.

Zhou Q, Munger M, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK and NLazar BR: Coexpression of Tim-3 and PD-1 identifies a CDS+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 117: 450-4510, 2011.

Dalotto-Moreno T, Croci D, Cerlier JP, Martinez-Allo VC, Dergan-Dyson S, Mendez-Huergo SP, Stupiwrski J, Mazal D, Osinaga E, Toscano MA, et al: Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Cell 21: 1107-1117, 2013.

Cedeno-Laurent F, Watanabe R, Teague JE, Kupper TS, Clark RA and Dimitrov CJ: Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 119: 3534-3538, 2012.

Hallek M, Cheson BD, Catovsky D, Caligaris-cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute Working Group 1996 guidelines. Blood 110: 4685-4692, 2008.

Hallek M: Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol 90: 446-460, 2015.

Eichhorst B, Bobak T, Montserrat E, Ghia P, Hillmen P, Hallek M and Buske C; ESMO Guidelines Committee: Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26 (Suppl 5): v78-v84, 2015.

Croci DO, Morande PE, Dergan-Dyson S, Borge M, Toscano MA, Stupiwrski JC, Bezerra RF, Avalos I, Nathuitz M, Gamberale R, et al: Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia 27: 1431-1446, 2013.

Kikushige Y, Yuda J, Jabbarzadeh-Tabarzi S, Shima T, Takayanagi S, Niito H, Yurino A, Miyawaki K, Takazaka K, et al: A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell 17: 341-352, 2015.
48. Gonçalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G, et al: The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine 22: 44-57, 2017.

49. Li X, Chen Y, Liu X, Zhang J, He X, Teng G and Yu D: Tim3/Gal9 interactions between T cells and monocytes result in an immune-suppressive feedback loop that inhibits Th1 responses in osteosarcoma patients. Int Immunopharmacol 44: 153-159, 2017.

50. Ozkazanc D, Yoyen-Ermis D, Tavukcuoglu E, Buyukasik Y and Esenbadgli G: Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells. Immunology 149: 460-471, 2016.

51. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, von Pawel J, Dols MC, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255-265, 2017.

52. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 387: 1837-1846, 2016.

53. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377: 1345-1356, 2017.

54. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387: 1540-1550, 2016.

55. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833, 2016.

56. Hurtado AM, Chen-Liang TH, Przychodzen B, Hamedic C, Muñoz-Ballester J, Dienes B, Garcia-Malo MD, Antón AI, de Arriba F, Teruel-Montoya R, et al: Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia. Blood Cancer J 5: c342, 2015.

57. Sato M, Nishi N, Shoji H, Seki M, Hashidate T, Hirabayashi Y, Kasai Ki K, Hata Y, Suzuki S, Hirashima M and Nakamura T: Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. Glycobiology 12: 191-197, 2002.